Company: HRTX
Filing Date: 2025-02-20
Form Type: 8-K
Source: 0000950170-25-023958
Chunk: 0

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-02-20
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01.

Entry into a Material Definitive Agreement.

On February 13, 2025, Heron Therapeutics, Inc. (the “ Company”), together with certain of its subsidiaries, entered into an amendment (the “ First Amendment”) to that certain Working Capital Facility Agreement, dated August 9, 2023 (the “ Loan Agreement”), with Hercules Capital, Inc., as administrative agent and collateral agent, and the several banks and other financial institutions or entities from time to time parties thereto.

The First Amendment amends the Loan Agreement to extend the maturity date under the Loan Agreement to the earlier of (a) September 1, 2027 and (b) to the extent that any of the Company’s 1.5% Convertible Senior Notes due May 24, 2026 (the “ Notes”) remain outstanding on such date, (i) May 12, 2026 or (ii) in the event that the maturity date of any of the Notes is extended, prior to May 12, 2026, to August 11, 2026 or later, the date that is ninety-one days prior to the maturity date of such further extended Notes.

The foregoing description of the First Amendment is qualified in its entirety by reference to the First Amendment, which is filed hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.